Merck, Pfizer drug combo extends kidney cancer survival: study
(Reuters Health)

16 february 2019 23:49:03

A combination of Merck & Co`s immunotherapy Keytruda and Pfizer Inc`s Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.

3 viewsCategory: Science > Medicine

How Much Will Americans Sacrifice for Good Health Care?
(WorldNews Health)
Gordon Banks gave touching last gift to charity just two weeks before he died
(WorldNews Health)

Merck, Pfizer drug combo extends kidney cancer survival: study(Reuters Health)

16 february 2019 23:49:03

Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice. Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten

Merck, Pfizer drug combo extends kidney cancer survival: study
(Reuters Health)

Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten